Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Patient and caregiver productivity loss and indirect costs associated with cardiovascular events in Portugal

Autor: Marques, Nuno, Gerlier, Laetitia, Ramos, Mafalda, Pereira, Helder, Rocha, Sérgia, Fonseca, Ana Catarina, André, Ana, Melo, Ricardo, Sidelnikov, Eduard

Publikováno v: In Revista Portuguesa de Cardiologia February 2021 40(2):109-115

Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach

Autor: Foos, Volker, Wang, Ke, McEwan, Phil, Zhang, Yanlei, Xin, Ping, Jiang, Xiaohua, Qu, Shuli, Xiong, Tengbin, De Moor, Raf, Ramos, Mafalda, Lamotte, Mark, Ji, Linong

Publikováno v: In Value in Health Regional Issues May 2019 18:36-46

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark

Autor: Ehlers, Lars H., Lamotte, Mark, Ramos, Mafalda C., Sandgaard, Susanne, Holmgaard, Pia, Kristensen, Malene M., Ejskjaer, Niels

Publikováno v: Ehlers, L H, Lamotte, M, Ramos, M C, Sandgaard, S, Holmgaard, P, Kristensen, M M & Ejskjaer, N 2022, ' The Cost-Effectiveness of Subcutaneous Semaglutide Versus Empagliflozin in Type 2 Diabetes Uncontrolled on Metformin Alone in Denmark ', Diabetes Therapy, vol. 13, no. 3, pp. 489-503 . https://doi.org/10.1007/s13300-022-01221-3

Introduction: International and Danish guidelines recommend the use of glucagon-like peptide 1 receptor agonists (GLP-1 RA) and sodium–glucose cotransporter 2 (SGLT-2) inhibitors already in second line in the management of type 2 diabetes (T2D). Th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4d16b0a686f40f5ea17206db9cba0a08
https://doi.org/10.1007/s13300-022-01221-3